VAS

AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023

Retrieved on: 
Tuesday, November 7, 2023
Patient, Rheumatology Research Foundation, Standard of care, Psoriasis, Headache, American College, VAS, Diarrhea, Research, Nausea, REM, MACR, Common, Amgen, University of Washington School of Medicine, Joint, University, AMGN, American College of Rheumatology, Nonsteroidal anti-inflammatory drug, Safety, LDA, Pain, ACR, BSA, Hospital, Body surface area, Disability, Psoriatic arthritis, Pharmaceutical industry, Medical imaging, Rheumatology

THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years. Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.

Key Points: 
  • Placebo
    THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis.
  • FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years.
  • Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.
  • "These patients experienced a significant reduction in psoriatic disease activity, a crucial finding for those in the early stages of the condition."

REGENATIVE LABS AND DR. ROBERT PARKER ANNOUNCE NEW CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN ACHILLES TENDON DEFECTS

Retrieved on: 
Tuesday, November 7, 2023
Achille, VAS, Connective tissue, Incidence, Physician, Acetate, Publication, Umbilical cord, Achilles tendon, Research, Athlete, Foot, Tissue, Medicine, Laser, Tendon, General practice, Phosphate, Pain, Patient, Medical device, Medical imaging, Veterinary medicine, Ankle, Regenerative medicine

PENSACOLA, Fla., Nov. 7, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case report demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Achilles tendon defects. 

Key Points: 
  • PENSACOLA, Fla., Nov. 7, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case report demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Achilles tendon defects.
  • The homologous use application validated by Dr. Parker sets a precedent for non-surgical allograft application.
  • The rising annual number of surgeries is enough to implement conservative protocols alternative to invasive surgical repair of the Achilles tendon.
  • This is just one of many homologous-use applications in regenerative medicine to improve patient outcomes," shared Regenative Labs CEO Tyler Barrett.

InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial

Retrieved on: 
Friday, November 3, 2023
FDA, Stem Cells, Pharmaceutical, Surgery, Physical Therapy, Managed Care, General Health, Hospitals, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Medical Supplies, Patient, Insurance, VAS, RT, Syndrome, Ludwig Maximilian University of Munich, Literature, Policy, Treatment, Visual analogue scale, Khaneqah Bala va Pain, Injection, OA, Pain, CSI, Osteoarthritis, KOOS, Evidence-based medicine, Cell, Clinical trial, Guideline, Knee, Emory University, MILES, Total, Knee pain, Gottschalk, Pharmaceutical industry, Medical imaging, InGeneron

InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA).

Key Points: 
  • InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA).
  • Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.
  • At InGeneron, we are dedicated to evidence-based medicine and deeply value our partnerships with respected institutions like Emory University.
  • Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.

South Korean Space Startup TelePIX Partners with Mexican Geo-Info Company Thrusters Unlimited for Latin America and Caribbean Market Expansion

Retrieved on: 
Thursday, November 2, 2023
Carbon, VAS, Prize, Seumas McNally Grand Prize, Observation, Multimedia, Ministry, MOU, Partnership, Ministry of Planning and Finance (Myanmar), Inter-American Development Bank, Thruster, Blue carbon, SatRevolution, Climate change, LAC, Drug, Surveying

SEOUL, South Korea, Nov. 2, 2023 /PRNewswire/ -- TelePIX, a leading South Korean space startup, announced the signing of a Memorandum of Understanding (MOU) with Thrusters Unlimited, a Mexican geo-information company.

Key Points: 
  • SEOUL, South Korea, Nov. 2, 2023 /PRNewswire/ -- TelePIX, a leading South Korean space startup, announced the signing of a Memorandum of Understanding (MOU) with Thrusters Unlimited, a Mexican geo-information company.
  • This partnership marks a significant milestone in TelePIX's strategic expansion efforts into global markets, including Central and South America, as well as Europe.
  • In return, Thrusters Unlimited will contribute crucial market insights and potential customer leads for satellite and VAS services in the Latin America and Caribbean market.
  • Earlier this year, the company solidified a business agreement with Mexican space company Space Zero Gravity on June 2nd.

Satellite-based Earth Observation Market size to grow by USD 7.60 billion during 2023-2028| Use of satellites for advanced environment monitoring to drive the market growth- Technavio

Retrieved on: 
Tuesday, October 31, 2023
Printing, Intelligence, VAS, Satellite, TB, LBS, System, Raytheon Technologies, Observation, Data management, OHB SE, Airbus, Nature, OHB, Growth, Database, Weather, Thales Group, EO, SE, USD, Northrop Grumman, YOY, LEO, Lockheed Martin, Investment, Defense, Communication, L3Harris Technologies, Surveying, Communications satellite, Energy, Data, Geography

NEW YORK, Oct. 31, 2023 /PRNewswire/ -- The Satellite-based Earth Observation Market size is expected to increase by USD 7.60 billion, accelerating at a CAGR of over 10.67% during the forecast period.

Key Points: 
  • NEW YORK, Oct. 31, 2023 /PRNewswire/ -- The Satellite-based Earth Observation Market size is expected to increase by USD 7.60 billion, accelerating at a CAGR of over 10.67% during the forecast period.
  • The report analyses the market size and growth and provides accurate predictions on the growth of the market.
  • Satellite-based Earth Observation Market 2024 – 2028: Market Dynamics:
    Advancements in satellite sensors and constellations result in substantial daily earth observation data.
  • Some satellites alone produce over 4TB of imagery data daily, enhancing precision in monitoring various Earth activities.

Tecnotree Reports Record Order Book Backed by Strong Deliveries, Promises Stable Growth

Retrieved on: 
Friday, October 27, 2023
5G, Telecommunications, Software, Artificial Intelligence, Data Management, Professional Services, Technology, Fintech, Diamond, Digital, Euro, MTN, VAS, BSS, Customer experience, Business support system, TM Forum, Fédération Aéronautique Internationale, Multimedia, API, CSP, Growth, Autonomy, Digital journalism, EUR, Sensa, Digital wallet, Telenor, VMS, AI, Metamorphosis, Investment, Digital transformation, Software as a service, Medical device, Video game, Health care, Tecnotree, MTN Uganda

View the full release here: https://www.businesswire.com/news/home/20231027241013/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231027241013/en/
    Tecnotree Reports Record Order Book Backed By Strong Deliveries, Promises Stable Growth (Graphic: Business Wire)
    Key highlights of the third quarter financial results:
    Net sales in the third quarter were EUR 21.4 million, showing 7.4% growth compared to last year
    Commenting on the results for the third quarter of 2023, Padma Ravichander, CEO of Tecnotree Corporation, said, “We are pleased with our performance this quarter as we maintain an ongoing momentum of consistent growth despite challenging market conditions.
  • Tecnotree signed a multi-million Euro, 5-year agreement with Telenor Group, to supply Tecnotree Voice Mail System (VMS) for Norway, Denmark and Sweden operations in the Nordic region.
  • Under this new agreement, Tecnotree will provide support to Telikom through its BSS-Edge platform, with products like mobile & fixed line business integration.
  • Additionally, Tecnotree continues its investments in new initiatives – Tecnotree Sensa Fabric AI/ML platform, Tecnotree Moments, Tecnotree DiWa (Digital Wallet), and SaaS; and had successful participation in many global technology events this quarter.

Five-Year Study Outcomes of the NuVasive Simplify Cervical Disc were Presented at the North American Spine Society 38th Annual Meeting

Retrieved on: 
Tuesday, October 24, 2023
Simplification, VAS, North American Spine Society, NYSE, Globus Medical, ACDF, NASS, Spine, Visual analogue scale, Contraindication, Annual general meeting, Overalls, NDI, Motion, Birth control

AUDUBON, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, presented five-year outcomes from the NuVasive Simplify Cervical Disc study at the North American Spine Society (NASS) 38th Annual Meeting.

Key Points: 
  • AUDUBON, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, presented five-year outcomes from the NuVasive Simplify Cervical Disc study at the North American Spine Society (NASS) 38th Annual Meeting.
  • The study demonstrates positive, long-term clinical outcomes, a high rate of overall composite success at 60 months, and statistical superiority to anterior cervical discectomy fusion (ACDF) procedural outcomes.
  • “Having clinically backed, long-term data for the Simplify Cervical Disc validates the promising clinical data we saw Simplify having at the two-year mark,” said Kyle Malone, senior vice president, Scientific Affairs of Globus Medical.
  • Dr. Pierce Nunley of the Spine Institute of Louisiana expressed his enthusiasm about the durability of the positive outcomes observed at 24 months.

Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress

Retrieved on: 
Tuesday, October 24, 2023
MRI, VAS, CSO, Physical examination, AAV, Osteoarthritis, WOMAC, Clinical trial, Congress, OA, Infectious Diseases Society of America, PALO, Arthralgia, Pain, Inflammation, HIV disease progression rates, Society, Ice, Rest, DSM-IV codes, Disease, Cell, ESGCT, Blood, Disability, Safety, Vasopressin receptor 2, Office of Inspector General, U.S. Department of Health and Human Services, Synovial fluid, Patient, Pharmaceutical industry, Nursing, Vaccine

Study findings noted elevated IL-1Ra expression in synovial fluid and an encouraging trend in symptomatic improvement.

Key Points: 
  • Study findings noted elevated IL-1Ra expression in synovial fluid and an encouraging trend in symptomatic improvement.
  • These data will be delivered in a poster presentation at the European American Society of Gene & Cell Therapy's (ESGCT) 30th Annual Congress being held October 24-27, 2023, in Brussels, Belgium.
  • Clinical trial participants developed various degrees of anti-AAV neutralizing antibodies after injection of GNSC-001, but no capsid targeted T-cell response was detected.
  • The study was supported by funding from the U.S. Department of Defense Peer Reviewed Medical Research Program (PRMRP).

BICS, Cellusys, Comfone, iBASIS, Mobileum & Syniverse Leads Champion Roaming Vendors: Kaleido Intelligence

Retrieved on: 
Tuesday, October 10, 2023
Syniverse, Signal, Research, Strategy, IBasis, BICS, Settlement, Voice over LTE, Philosophy, Kaleido Star, Internet of things, VAS, IPX, Mobile phone, Retail, Animal husbandry

The Roaming Vendor Hub: Competitive Analysis 2023 research analysed 51 established roaming vendors and wholesale providers.

Key Points: 
  • The Roaming Vendor Hub: Competitive Analysis 2023 research analysed 51 established roaming vendors and wholesale providers.
  • BICS, Cellusys, Comfone, iBASIS, Mobileum and Syniverse were scored the Number 1 Champion vendors across multiple product categories.
  • These categories encompassed Steering Of Roaming, Sponsored Roaming, Roaming Hubs, IPX, Roaming Analytics & VAS, Clearing & Settlement, Fraud Management, as well as Signalling Security & Firewall.
  • The Number 1 and Champion vendors across key roaming product segments as scored by Kaleido Intelligence are included in the accompanying infographic.

Tecnotree Announces Signing of a Multi-Million Deal with an Emerging CSP from Africa to Deliver Digital BSS, Fintech & VAS Services

Retrieved on: 
Tuesday, October 17, 2023
Professional Services, Business, Technology, 5G, Networks, Artificial Intelligence, Diamond, Partnership, Health, Africa Scout Region (World Organization of the Scout Movement), Charge density, TM Forum, 3GPP, AI, Fintech, API, AIML, Mediation, G, Digital, Business support system, Education, CRM, OTT, BSS, DSPS, Digital wallet, ODA, VAS, Diwa, Mobile phone, Online shopping, Tecnotree

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, announced the signing of a new multimillion-dollar, five-year contract with an emerging telco services provider from the African Region, to provide a full digital BSS stack along with Fintech and Value-Added Services (VAS) services.

Key Points: 
  • Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, announced the signing of a new multimillion-dollar, five-year contract with an emerging telco services provider from the African Region, to provide a full digital BSS stack along with Fintech and Value-Added Services (VAS) services.
  • The agreement aims to facilitate seamless end-to-end order to cash services for retail and enterprise customers.
  • Tecnotree’s 5G-ready BSS suite is agile, cloud-native, and Diamond-certified by TM Forum for real-world Open APIs.
  • The deployment also includes customer value enablement via self-service enablement, partner loyalty services & gamification, real-time campaigns, Digital Wallet (DiWa) services, and new age digital VAS services.